Experience with PCSK9 inhibitors from a Nephrology unit
Nefrologia (Engl Ed)
.
2024 Jan-Feb;44(1):111-113.
doi: 10.1016/j.nefroe.2024.02.007.
Epub 2024 Feb 28.
Authors
Verónica Escudero Quesada
1
,
Jonay Pantoja Pérez
2
,
Cristina Castro Alonso
2
,
July Vanessa Osma Capera
2
,
Alejandro Valero Antón
2
,
Asunción Sancho Calabuig
2
Affiliations
1
Servicio de Nefrología, Hospital Universitario Dr. Peset, Valencia, Spain. Electronic address: veesque@gmail.com.
2
Servicio de Nefrología, Hospital Universitario Dr. Peset, Valencia, Spain.
PMID:
38423835
DOI:
10.1016/j.nefroe.2024.02.007
No abstract available
Publication types
Letter
MeSH terms
Anticholesteremic Agents*
Nephrology*
PCSK9 Inhibitors
Proprotein Convertase 9
Substances
PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9
Anticholesteremic Agents